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CHAPTER 5
Sonya M. Balukova, Bartholomeus C.M. Haarman,  
Rixt.F. Riemersma – van der Lek, Robert A. Schoevers
International Journal of Bipolar Disorders. 2016 Dec;4(1):14. 
Does CRP predict 
outcome in bipolar 





The association between inflammation and the course of mood disorders is receiving 
increased attention. This study aims to investigate whether a sub-group of patients 
with BD can be identified for which a higher CRP (C-reactive protein) level at baseline 
is associated with an unfavorable prognosis. 
Methods
Historic cohort study using CRP at baseline, with 15 months follow-up of mood 
 status and medication. Cross-sectional analyses include boxplots, one-way ANOVA, 
 Receiver Operating Characteristics (ROC) curve and chi-square test, and the longitu-
dinal analysis using multivariate Cox-regression.
Results
84 bipolar disorder patients were included in the analyses. Cross-sectionally, no 
statistically significant difference was found in CRP distribution across mood states 
(p=0.372) or rapid cycling state (p=0.656). Also, no CRP cut-off level was distin-
guished between euthymic and non-euthymic patients according to the ROC curve 
(p=0.449, AUC=0.452, 95%CI: 0.327, 0.576), and a literature-derived cut-off value 
(3 mg/L) again demonstrated no difference (p=0.530). Longitudinally, no associa-
tion was found between CRP and prognosis of disease neither in euthymic (-2 Log 
Likelihood= 120.460; CRP: p=0.866, B= -0.011, OR= 0.989 (95% CI: 0.874 – 1.120) 
or non-euthymic patients (-2 Log Likelihood= 275.028; CRP: p=0.802, B= 0.010, 
OR=1.010 (95% CI: 0.937 – 1.088)). Medication use did not affect these associations.
Conclusions
We found no statistically significant association between CRP and a more unfavor-
able BD prognosis, suggesting that the application of CRP as a practical biomarker to 
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Background
Bipolar disorder (BD) is associated with a significant decrease in quality of life and 
 social functioning of patients1. Despite the availability of pharmacological treatment, 
its efficacy is far from optimal2,3. A promising approach for optimizing the treatment 
is to tailor it to the specific characteristics of a patient as part of a ‘personalized 
 medicine’ approach which encompasses not only psychological but also biological 
markers4. 
There is increasing evidence to suggest that immunological processes may con-
tribute to the emergence as well as the prognosis and severity of BD5. Apart from 
 pro-inflammatory cytokines such as IL-2 and IL-66, C-reactive protein (CRP) is an 
acute phase protein that is produced in response to infection and inflammation. It 
is also considered to be another candidate biomarker for detecting immune dysreg-
ulation in BD. A number of studies suggest an association between CRP and mood 
 disorders, especially during a manic episode7–9. 
Based on the idea that immunological processes play a role in the pathophysiology of 
BD, it can be hypothesized that an increased activity of these processes, measured 
with CRP, would lead to more instability in BD symptomatology and course of disease. 
Increased inflammatory activity has been shown to be related to therapy resistance 
and chronicity in unipolar depression10–12. Recently, Becking et al.13 demonstrated an 
increased CRP to predict future development of manic symptoms in a sample of MDD 
(major depressive disorder) patients, also suggesting that this is a subtype with an 
untoward prognosis. However, to date, no studies have examined this issue in bipolar 
patients. 
The current study investigated whether, in a clinical setting, higher CRP levels at 
 baseline may predict a worse BD outcome, defined as a shorter time to relapse (if 
 euthymic) or a longer time to recover. As some medication may influence inflammatory 
processes, this was taken into account.
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Methods
Participants and ethical considerations
For the present historic cohort study we used medical files from 84 BD patients 
from the BD outpatient department of the psychiatry department of the University 
 Medical Center Groningen (UMCG), the Netherlands. 
Patients who provided a written informed consent to participate, were included if the 
following criteria were fulfilled: DSM-IV-TR diagnosis of BD, age between 18 and 65, 
recorded CRP value, not pregnant or less than 6 months postpartum, no current seri-
ous somatic illnesses (current infections or liver disease, serious un- or undertreated 
heart, lung or neurological disorders). 
All patient data were collected as part of regular outpatient care and were anony-
mously used for research according to the Data Protection Act (WBP) and Medical 
Treatment Agreement (WGBO), as formulated in the Code of Conduct for the Use of 
Data in Health Research, also known as the Research Code of Conduct (see also IRB 
in Supporting Information. 
Assessments of study parameters
The study parameters included CRP, measurement date and value, BD type, presence 
of a rapid cycling course, and mood episodes and medication one month before and 
15 months following the CRP measurement.
Assessment of the psychiatric condition of patients was determined by the first 
 author based on information from two sources: the electronic medical records of the 
treating psychiatrists and the LifeChart Methodology (LCM) records– (a systemat-
ic collection of data on the course of illness and treatment presented in a graphical 
form)14. The condition was noted as one of five categories: 0. Euthymia; 1. Depressive 
episode; 2. Hypomania or mania; 3. Mixed episode; 4. Unstable mood. Longer- lasting 
clinically significant mood instability that did not fulfill the criteria for any mood 
 episode was assessed as an “unstable” mood, while subthreshold symptoms were 
assessed as no change in episode15. 
Serum CRP (high sensitive CRP) is routinely measured at hospital admission in this 
Psychiatry department (and additional measurements are performed when there is a 
psychiatric or somatic event for a patient). CRP was assayed using a wide range turbi-
dimetric CRP assay (CRPL3 assay) on a Roche Modular platform (Roche, Mannheim, 
Germany). Starting from the CRP measurement date at baseline (T0), the time to 
episode change (T1) and the corresponding psychiatric condition were gathered from 
the medical file. 
Cases with unclear information and/or diagnosis of current mental status were 
 discussed with the psychiatrists of the BD outpatient department. Remaining 
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Statistical analysis
Both cross-sectional and longitudinal analyses were performed. Cross-section-
ally, data were visualized using boxplots and tested using histograms, P-P plots, 
 Kolmogorov-Smirnov test, Kruskal-Wallis, a receiver operating characteristics (ROC) 
curve and Fisher’s exact test. 
The longitudinal analysis comprised a multivariate Cox-regression based on the time 
passed until a change of episode has occurred where the main covariate was the scale 
of CRP values. This analysis was done separately for euthymic patients and those 
who were in a mood episode at baseline (depressed, manic, mixed, unstable). This 
was done because the variable signifying elapsed time has a different meaning for 
patients in an euthymic state than for a non-euthymic one, and should thus be inter-
preted differently to describe the progression of disease. Longer time before episode 
change signifies a better BD prognosis if a subject is euthymic (means longer time in 
remission), but it means a worse course if a subject is non-euthymic (means longer 
time in an episode). 
Medication was added to the Cox-regression to examine whether it affected 
CRP or changed the effect of CRP on BD progress. Separate analyses were done 
 after  excluding those non-psychopharmaceutical drugs that are known to have 
 anti-inflammatory and/or CRP-affecting properties16–18. 
As part of sensitivity analyses, all tests were repeated in each of the following sub-
groups for each timepoint and then for the whole study: excluding subjects taking 
anti-inflammatory medication; excluding all medication that affects CRP; excluding 
outliers, defined as CRP values above 10 mg/L.
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Results
The sample of this study consisted of 84 patients and Table 1 shows their character-
istics. Testing the data for normality showed a non-normal distribution of the CRP 
data, with a positive skewness and a significant difference from a normal distribution 
seen by Kolmogorov-Smirnov test (D(84)=0.258, p<.001). Because of this, median 
values are provided for each mood state in table 1. 
Cross-sectional analysis
The differences between the distribution of CRP values among the mood states 
were first examined using Kruskal-Wallis. No statistical significance was found 
(p=0.372) (see table 1). Figure 1 shows the distribution of mood episodes at base-
line. Using Kolmogorov-Smirnov no statistical significant difference was found 
 between the patients that were rapid cycling and patients that were not (p=0.656, 
see  figure 2). Repeating the cross-sectional analyses excluding all medications that 
are known to affect CRP, as well as excluding CRP outliers, generally yielded the same, 
 non-significant results.
TABLE 1 
Characteristics of patient population
 Euthymic Depressed (Hypo)manic Mixed Unstable All 
Mean age (SD) 44.9 (12.4) 42.7 (12.4) 43.2 (10.3) 46 (7.1) 40.5 (10.2) 43.6 (11.7) 
Number of Subjects (%) 37 (44.0) 27 (32.1) 12 (14.3) 2 (2.4) 6 (7.1) 84 (100) 
     Male Gender (%) 11 (37.9) 10 (34.5) 4 (13.8) 2 (6.9) 2 (6.9) 29 (34.5) 
     Female Gender (%) 26 (47.3) 17 (30.9) 8 (14.5) 0 4 (7.3) 55 (65.5) 
BD type I (%)* 26 (41.9) 21 (33.9) 11 (17.7) 2 (3.2) 2 (3.2) 62 (100) 
BD type II (%)* 7 (41.2) 5 (29.4) 1 (5.9) 0 4 (23.5) 17 (100) 
Rapid Cycling (%) 4 (30.8) 3 (23.1) 2 (15.4) 0 4 (30.8) 13 (100) 
Metabolic Syndrome (%)** 9 (13.8) 6 (9.2) 2 (3.1) 1 (1.5) 2 (3.1) 20 (30.8)*** 
Median C-reactive protein (mg/L)  1.10 2.10 0.90 3.08 1.39 1.37 
 
Abbreviations: SD =Standard Deviation; BD=bipolar disorder
* Bipolar disorder type information missing for 5 patients
** Metabolic syndrome information missing for 19 patients (Criteria: fasting glucose >5.6  
 mmol/L and two or more of following: BMI >30 kg/m2, Hypertriglyceridemia >1.7  
 mmol/L, HDL-C <0.9 mmol/L in men and <1.0 mmol/L in women, Hypertension > 140/90  
 mmHg)
***  The number in brackets in this cell represents the percentage of all subjects who  
 have   metabolic syndrome, while the rest of the percentages in this row represent  
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After excluding 6 CRP outliers, there were 37 (44%) who were in euthymia and 47 
(56%) were non-euthymic: 27 (32.1%) were in a depressive episode, 12 (14.3%) in a 
manic episode, 2 (2.4%) in a mixed episode and 6 (7.1%) were unstable. 
Using a ROC curve, the data was tested to identify a cut-off value of CRP which could 
suggest whether subjects at baseline would be euthymic or in an episode. Based on 
the curve (Figure S1 in Supporting Information), no such cut-off value was found 
(AUC=0.452,p=0.449, 95%CI: 0.327, 0.576).
Consequently, the cross-sectional analyses were performed using a literature-based 
CRP cut-off value of 3.0 mg/L and a chi-square test for the not-normal distribution 
of CRP value. The results showed that, cross-sectionally, higher CRPs were almost 
equally distributed among euthymic and non-euthymic patients (42.1% euthymic 
and 57.9% non-euthymic by CRP>3mg/L; 44.6% euthymic and 55.4% non-euthymic 
by CRP≤3mg/L). Fisher’s exact test confirmed that these results have no statistical 
 significance (p=0.530). 
The Y-axis depicts CRP concentration in mg/L starting from 0 mg/L and incrementing 
with 5 mg/L. On the X-axis bars signify the interquartile range of CRP values in each mood 
group, and the thickened line inside them shows the median value of CRP within this mood 
group. The stars and circle show the boxplot outliers, while the numbers next to them 
signify the specific number of the patient with this outlier value. The circle is a patient with 
CRP value closest to the threshold value but above it, so it is also not included.
FIGURE 1 
Boxplot of CRP distribution at baseline across mood state
88
Longitudinal analysis
For euthymic subjects at baseline
From the 37 subjects who were euthymic at Baseline, 20 had a change of episode 
during the trial period, while 17 patients stayed euthymic. The results are shown in 
 table 2 and the hazard function of the covariate CRP is on figure 3. There is no cor-
relation between CRP value and the event of episode change (relapsing). The odds 
The Y-axis depicts CRP concentration in mg/L starting from 0 mg/L and incrementing with 
5 mg/L. On the X-axis bars signify the interquartile range of CRP values in each patient 
group, and the thickened line inside them shows the median value of CRP within this mood 
group. The stars and circle show the boxplot outliers, while the numbers next to them 
signify the specific number of the patient with this outlier value.
FIGURE 2 
Boxplot of CRP distribution between patients with and without  
rapid cyclingline
TABLE 2 
Longitudinal results from Cox regression
Patient Group 







95% CI of Odds Ratio 
Lower Upper 
Euthymic Patients at 
Baseline 
120.460 .866 -.011 .989 .874 1.120 
Non-Euthymic Patients at 
Baseline 
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ratio (=0.989) approaches equality for both groups (results are very close to the 
 neutral line). Moreover, these findings are not statistically significant and so the null 
hypothesis could not be rejected. 
For non-euthymic subjects at baseline
There were 47 subjects who were in an episode at baseline of which 30 became 
 euthymic, while 17 patients remained in a mood episode during the study period. The 
results are shown in the table 2 and in figure 4. The odds ratio is approaching equality 
(results are very close to the neutral line) and these findings are not statistically sig-
nificant. As seen in the euthymic group, these results also do not show an association 
between CRP and relapsing.
After adjusting for covariates and testing for interactions of CRP with medication at 
the two timepoints, there were no results with statistical significance in each of the 
two mood-state groups – euthymic and non-euthymic. Adjusting for separate medi-
cation types used in any moment during the study again yielded no associations with 
statistical significance.
This figure illustrates what the hazard ratio is for recovering of a subject with a given CRP 
value compared to a subject with a CRP value of one unit lower in the course of the studied 
period. The Y-axis represents the rate of recovering of all subjects sick at baseline. The 
elapsed time period in days until an euthym state has occurred is depicted on the X-axis.
FIGURE 3 
Hazard function at mean of the covariate CRP for subjects euthymic at baseline
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TABLE 3 
Number of subjects per medication type
Parameter T0a T1b Totalc 
Lithium (%) 31 (36.9) 47 (56) 48 (57.1) 
Valproic acid (%) 14 (16.7) 9 (10.7) 16 (19.0) 
Anti-Inflammatory drugs (%)* 12 (14.3) 12 (14.3) 16 (19.0) 
Tricyclic Antidepressants (TCA) (%)*  5 (6.0) 5 (6.0) 7 (8.3) 
Antidepressants (non-TCA) (%) 31 (36.9) 27 (32.1) 32 (38.1) 
Antipsychotics (%) 35 (41.7) 34 (40.5) 39 (46.4) 
Benzodiazepines (%)  31 (36.9) 31 (36.9) 39 (46.4) 
 
a Medication used up to and including the baseline (T0);
b Medication used up to and including the time of episode change is such occurred (T1);
c Medication used for the total period of the study (1 month before and up to 15 months   
  after CRP measurement, unless episode change occurred earlier);
* Values are the same for both T0 and T1 timepoints;
This figure illustrates what the hazard ratio is for recovering of a subject with a given CRP 
value compared to a subject with a CRP value of one unit lower in the course of the studied 
period. The Y-axis represents the rate of recovering of all subjects sick at baseline. The 
elapsed time period in days until an euthym state has occurred is depicted on the X-axis.
FIGURE 4 
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Table 3 shows a summary of the used medication at the T0 and T1 timepoints as well 
as in total for the whole study period. 
Discussion
Principal findings
To our knowledge, this is the first study examining longitudinal associations between 
CRP level and clinical outcome in BD patients in a naturalistic treated and real-life 
measurement outpatient setting. In a first cross-sectional analysis, we could not 
distinguish a sub-group of BD patients with an elevated baseline CRP level based 
on affective state or rapid cycling state. In the longitudinal analysis, no statistically 
significant association was found between higher CRP values and relapsing in either 
euthymic or non-euthymic patients, as well as when comparing them. 
Comparison to previous studies
The results of the cross-sectional analysis can be compared to several previous 
 studies on the association of CRP with BD. Two of the studies with a total of 202 
patients reported that for their BD subjects higher CRP was significantly associated 
with manic state compared to the other mood episodes8,9.
Three other studies with a total of 248 patients however did not demonstrate 
 significant differences in CRP across the mood states, which is corresponding to the 
current study results19–21. 
The findings of the influence of medication on the reported associations between 
CRP values and mood states in the above studies are also conflicting. Hornig et al 19 
found a significant negative interaction between lithium and CRP within BD patients, 
while Dickerson et al.8 found that no medication affected the CRP association with 
BD, as we found in the current study.
In a recent meta-analysis Dargél et al. demonstrated an overall cross-sectional 
 association between BD and CRP22. In this meta-analysis, CRP levels were elevated 
in manic and euthymic patients compared to HC, but not in depressed BD patients 
compared to HC. Recent prospective longitudinal studies demonstrated CRP al-
terations across mood states23, as well as before and after various treatments24. In 
addition an increased CRP was found to be associated with an increased risk for 
 developing late-onset BD in a large Danish demographic sample25. Adding to this body 
of knowledge, the present study shows that using CRP as a practical biomarker to 
predict outcome in a naturalistic outpatient care setting is not as easily applicable as 
it may seem. 
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Limitations
The present study has several limitations. A limitation pertaining the use of histori-
cal data is that CRP measurements were more or less routinely measured, and more 
in those patients who were psychiatrically or somatically ill. Since it was not purely 
measured as a routine, a selection bias cannot be ruled out.
Furthermore, body fat percentage, smoking, blood pressure, physical activity and 
SNP polymorphisms are suggested to be associated with different baseline levels of 
CRP26–30 and in the present study we were not able to correct for these variations. 
Finally, the study would have benefitted from a larger sample size. 
Proposed mechanisms
There are two factors to consider which could play a role in shaping the results from 
this study: use of medication and the pathophysiological model of BD.
Due to the naturalistic design of this study, a great variety of medications was used, 
some of which have been suggested to have anti-inflammatory properties. Lithium, 
part of the standard treatment of dipolar disorder in the Netherlands, was used by 
more than half of the patients in this study (57.1%). Although its mechanism of action 
in bipolar depression is not fully understood yet16, several studies have found evidence 
that lithium causes a decrease in the inflammatory marker CRP11,19 and a similar effect 
is also described for SSRIs (selective serotonin reuptake inhibitors) used by 38% of 
the subjects here18. However, there are reports that lithium and antidepressants may 
also exhibit pro-inflammatory properties16,31,32. These properties were postulated 
 after observing the stimulating effect of lithium on pro-inflammatory cytokines such 
as Tumor Necrosis Factor-α (TNF-α), Interleukin-4 (IL-4) and Interleukin-6 (IL-6). It is 
not yet clear what causes these reverse effects. There could be various mechanisms 
via which medication is influencing CRP. However, at the same time no such effect 
was demonstrated in this study. Therefore other factors should be considered. 
Our findings therefore suggest that the inflammatory model of BD is probably much 
more complex than what can be shown by straightforward inflammatory alterations 
demonstrated by elevated markers such as CRP33 at one point in time.
Compared to the inflammatory mechanism in somatic disorders where CRP, being 
an acute phase protein, directly correlates to acute worsening of a disease, it may 
be that immunological processes in BD are affected by more factors and additional 
mechanisms, which need to be added to the model to gain a better understand-
ing. One such hypothesis is that inflammatory changes in psychiatric disorders are 
 mediated through a shift towards the tryptophan/kynurenine pathway, which leads 
to the  formation of further factors that may affect the functioning of the brain, such 
as  neurotoxic accumulation of the metabolite 3-Hydroxykynurenine34. Another 
 hypothesis is the co-occurrence of autoimmunity alongside immune dysregulation in 
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more pure immune activation35,36.
It has been suggested that the immune mediating pathogenesis of BD occurs at a 
much younger age, and what follows is a dysregulation of the bodily systems. The 
long-lasting results are then what we see at an older age: unhealthy and unexpected 
interactions and responses of the whole body, and of inflammatory markers as well37. 
Another interesting possibility is that what we see is not necessarily an inflamed but 
a damaged organism, given that CRP reacts not only to inflammatory stimuli, but also 
to damaged cells38. 
To increase our understanding of the position of immune-system-mediated patho-
physiological processes in BD it is necessary to measure CRP and other relevant 
 immune bio-assays prospectively in a larger sample size. In that regard it is important 
to investigate what happens on an intra-individual level: additional trials are necessary 
measuring CRP on different timepoints in a prospective longitudinal manner so that 
individual changes could be followed and analyzed. Perhaps, these studies will eluci-
date models, adjusting for variables known to influence CRP, that eventually enable 
CRP to be used as a practical biomarker to predict outcome in naturalistic treatment 
settings.
Acknowledgements
We thank dr. J.E. Kootstra-Ros for her valuable assistance in retrieving archived data.
94
References
1.  ten Have M, Vollebergh W, Bijl R, Nolen W a. Bipolar disorder in the general population in The 
Netherlands (prevalence, consequences and care utilisation): results from The Netherlands 
Mental Health Survey and Incidence Study (NEMESIS). J Affect Disord [Internet].  
2002 Apr;68(2–3):203–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12063148
2.  Frecska E, Balla P, Falussy L, Ferencz A, Varga Z. The message of the survival curves: I. 
Composite analysis of long-term treatment studies in bipolar disorder [Internet]. Vol. 14, 
Neuropsychopharmacologia Hungarica . 2012. p. 155–64. Available from:  
http://www.mppt.hu/images/magazin/pdf/xiv-evfolyam-3-szam/frecska.pdf
3.  Burcusa SL, Iacono WG. Risk for recurrence in depression. Vol. 27, Clinical Psychology Review. 
2007. p. 959–85. 
4.  Hamdani N, Doukhan R, Kurtlucan O, Tamouza R, Leboyer M. Immunity, inflammation, and bipolar 
disorder: diagnostic and therapeutic implications. Curr Psychiatry Rep [Internet]. 2013;15(9):387. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/23955004
5.  Liu HC, Yang YY, Chou YM, Chen KP, Shen WW, Leu SJ. Immunologic variables in acute mania of 
bipolar disorder. J Neuroimmunol. 2004;150(1–2):116–22. 
6.  Brietzke E, Stertz L, Fernandes BS, Kauer-Sant’Anna M, Mascarenhas M, Escosteguy Vargas A, et 
al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. 
J Affect Disord [Internet]. 2009 Aug [cited 2010 Aug 28];116(3):214–7. Available from:  
http://www.ncbi.nlm.nih.gov/pubmed/19251324
7.  Maes M, Smith R, Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. 
Psychoneuroendocrinology [Internet]. 1995 Jan [cited 2011 Mar 6];20(2):111–6. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/7899532
8.  Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive 
protein are associated with mania symptoms in outpatients with bipolar disorder. Prog 
Neuropsychopharmacol Biol Psychiatry [Internet]. 2007 May 9 [cited 2011 Jun 1];31(4):952–5. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/17391822
9.  Cunha AB, Andreazza AC, Gomes F a, Frey BN, da Silveira LE, Gonçalves C a, et al. Investigation of 
serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch 
Psychiatry Clin Neurosci [Internet]. 2008 Aug [cited 2011 Jun 1];258(5):300–4. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/18297417
10.  Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized 
controlled trial of the tumor necrosis factor antagonist infliximab for treatment-
resistant depression: the role of baseline inflammatory biomarkers. JAMA psychiatry 
[Internet]. 2013;70(1):31–41. Available from: http://archpsyc.jamanetwork.com/article.
aspx?articleid=1356541
11.  Sluzewska A, Sobieska M, Rybakowski JK. Changes in acute-phase proteins during lithium 
potentiation of antidepressants in refractory depression. Neuropsychobiology. 1997;35(3):123–7. 
12.  Miller AH, Maletic V, Raison CL. Inflammation and Its Discontents: The Role of Cytokines in the 
Pathophysiology of Major Depression. Biol Psychiatry [Internet]. 2009;65(9):732–41. Available 
from: http://dx.doi.org/10.1016/j.biopsych.2008.11.029
13.  Becking K, Boschloo L, Vogelzangs N, Haarman BCM, Riemersma-van der Lek R, Penninx 
BWJH, et al. The association between immune activation and manic symptoms in 
patients with a depressive disorder. Transl Psychiatry [Internet]. 2013 Jan [cited 2013 






e in bipolar disorder in regular outpatient care?
5
14.  Denicoff KD, Leverich GS, Nolen W a, Rush AJ, McElroy SL, Keck PE, et al. Validation of the 
prospective NIMH-Life-Chart Method (NIMH-LCM-p) for longitudinal assessment of bipolar 
illness. Psychol Med [Internet]. 2000 Nov [cited 2013 Sep 13];30(6):1391–7. Available from:  
http://www.ncbi.nlm.nih.gov/pubmed/11097079
15.  Perlis RH, Ostacher MJ, Marangell LB, Hongwei Z, Wisniewski SR, Ketter, Terrence a., et al. 
Predictors of Recurrence in Bipolar Disorder: Primary Program for Bipolar Disorder ( STEP-BD ). 
Am J Psychiatry. 2006;163(4):217–24. 
16.  Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, 
pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the 
literature. J Clin Psychiatry [Internet]. 2009 Aug;70(8):1078–90. Available from:  
http://www.ncbi.nlm.nih.gov/pubmed/19497250
17.  Ximenes JCM, de Oliveira Gonçalves D, Siqueira RMP, Neves KRT, Santos Cerqueira G, Correia AO, 
et al. Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory 
properties. Naunyn Schmiedebergs Arch Pharmacol [Internet]. 2013;386(7):575–87. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/23584602
18.  O’Brien SM, Scott L V, Dinan TG. Antidepressant therapy and C-reactive protein levels.  
Br J Psychiatry [Internet]. 2006;188:449–52.  
Available from: http://www.ncbi.nlm.nih.gov/pubmed/16648531
19.  Hornig M, Goodman D, Kamoun M, Amsterdam J. Positive and negative acute phase proteins in 
affective subtypes. J Affect Disord. 1998;49(1):9–18. 
20.  Hope S, Dieset I, Agartz I, Steen NE, Ueland T, Melle I, et al. Affective symptoms are associated 
with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. 
J Psychiatr Res [Internet]. 2011;45(12):1608–16.  
Available from: http://dx.doi.org/10.1016/j.jpsychires.2011.08.003
21.  Tsai S-Y, Chung K-H, Wu J-Y, Kuo C-J, Lee H-C, Huang S-H. Inflammatory markers and their 
relationships with leptin and insulin from acute mania to full remission in bipolar disorder.  
J Affect Disord [Internet]. 2012;136(1–2):110–6.  
Available from: http://www.ncbi.nlm.nih.gov/pubmed/21962564
22.  Dargél AA, Godin O, Kapczinski F, Kupfer DJ, Leboyer M. C-Reactive Protein Alterations in Bipolar 
Disorder. J Clin Psychiatry [Internet]. 2015 Feb 25;76(2):142–50. Available from:  
http://www.psychiatrist.com/jcp/article/pages/2015/v76n02/v76n0203.aspx
23.  Jacoby AS, Munkholm K, Vinberg M, Pedersen BK, Kessing LV. Cytokines, brain-derived 
neurotrophic factor and C-reactive protein in bipolar i disorder - Results from a prospective 
study. J Affect Disord [Internet]. 2016;197:167–74. Available from: http://dx.doi.org/10.1016/j.
jad.2016.03.040
24.  Uyanik V, Tuglu C, Gorgulu Y, Kunduracilar H, Uyanik MS. Assessment of cytokine levels  
and hs-CRP in bipolar I disorder before and after treatment. Psychiatry Res [Internet]. 
2015;228(3):386–92. Available from: http://dx.doi.org/10.1016/j.psychres.2015.05.078
25.  Wium-Andersen MK, Ørsted DD, Nordestgaard BG. Elevated C-reactive protein and  
late-onset bipolar disorder in 78 809 individuals from the general population. Br J Psychiatry. 
2016;208(2):138–45. 
26.  Marnell L, Mold C, Du Clos TW. C-reactive protein: Ligands, receptors and role in inflammation. 
Clin Immunol. 2005;117(2):104–11. 
27.  Palosuo T, Husman T, Koistinen J, Aho K. C-reactive protein in population samples. Acta Med 
Scand [Internet]. 1986;220(2):175–9.  
Available from: http://www.ncbi.nlm.nih.gov/pubmed/3776692
28.  Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in 
overweight and obese adults. JAMA [Internet]. 1999 Dec 8;282(22):2131–5. Available from:  
http://www.ncbi.nlm.nih.gov/pubmed/10591334
96
29.  Davey Smith G, Lawlor DA, Harbord R, Timpson N, Rumley A, Lowe GDO, et al. Association of 
C-reactive protein with blood pressure and hypertension: life course confounding and mendelian 
randomization tests of causality. Arterioscler Thromb Vasc Biol [Internet]. 2005 May;25(5):1051–
6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15731495
30.  Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. 
adults. Epidemiology [Internet]. 2002 Sep;13(5):561–8.  
Available from: http://www.ncbi.nlm.nih.gov/pubmed/12192226
31.  Hamer M, Batty GD, Marmot MG, Singh-Manoux A, Kivimäki M. Anti-depressant medication 
use and C-reactive protein: Results from two population-based studies. Brain Behav Immun 
[Internet]. 2011;25(1):168–73. Available from: http://dx.doi.org/10.1016/j.bbi.2010.09.013
32.  Nassar A, Azab A. Effects of Lithium on Inflammation. ACS Chem Neurosci [Internet]. 
2014;5:451–8. Available from: http://pubs.acs.org/doi/abs/10.1021/cn500038f
33.  Altamura a. C, Buoli M, Pozzoli S. Role of immunological factors in the pathophysiology and 
diagnosis of bipolar disorder: Comparison with schizophrenia. Psychiatry Clin Neurosci. 
2014;68(1):21–36. 
34.  Myint A-MMA, Kim Y-KKY. Network beyond IDO in psychiatric disorders: revisiting 
neurodegeneration hypothesis. … Neuro-Psychopharmacology Biol Psychiatry [Internet]. 2013 Jan 
3 [cited 2014 Sep 17];48:304–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24184687
35.  Rege S, Hodgkinson SJ. Immune dysregulation and autoimmunity in bipolar disorder: Synthesis 
of the evidence and its clinical application. Aust N Z J Psychiatry [Internet]. 2013;47(12):1136–51. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/23908311
36.  Haarman BCM, Riemersma-Van der Lek RF, Burger H, Netkova M, Drexhage RC, Bootsman F, et 
al. Relationship between clinical features and inflammation-related monocyte gene expression in 
bipolar disorder - towards a better understanding of psychoimmunological interactions. Bipolar 
Disord [Internet]. 2014 Mar 29 [cited 2014 Apr 23];16(2):137–50. Available from:  
http://www.ncbi.nlm.nih.gov/pubmed/24286609
37.  Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein HC, et al. The immune 
theory of psychiatric diseases: a key role for activated microglia and circulating monocytes.  
J Leukoc Biol [Internet]. 2012 Aug 8 [cited 2012 Nov 1];92(September):1–17. Available from:  
http://www.ncbi.nlm.nih.gov/pubmed/22875882






e in bipolar disorder in regular outpatient care?
5

PART 2 
Neuroimmune 
system

